Canakinumab for the treatment of hyperimmunoglobulin D syndrome
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2019.1571410
Abstract: ABSTRACT Introduction: Mevalonate Kinase Deficiency (MKD) is a rare monogenic autoinflammatory disorder (AID) with autosomal recessive inheritance caused by mutations in the MVK gene. It includes hyperimmunoglobulinemia D syndrome (HIDS) and mevalonic aciduria (a severe… read more here.
Keywords: canakinumab; canakinumab treatment; hyperimmunoglobulin syndrome; treatment ... See more keywords
Long-term Efficacy and Safety of Canakinumab in the Treatment of Systemic Juvenile Idiopathic Arthritis in Japanese Patients: Results from an Open-label Phase III Study.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac128
Abstract: OBJECTIVES To report the efficacy and safety of canakinumab treatment in Japanese patients with systemic juvenile idiopathic arthritis over a 48-week study period. METHODS Patients were administered canakinumab 4 mg/kg (maximum dose 300 mg) every 4 weeks,… read more here.
Keywords: rheumatology; canakinumab treatment; systemic juvenile; study ... See more keywords